Daily Dilution Report - Apr 29, 2026
All Events
$GDC (MC: $227M)
- ATM Program for up to $300M (up to 71.6M shares) at an illustrative $4.19/share.
- Equity Line Agreement for up to $300M, shares to be issued at 90% of lowest VWAP (min $0.44).
- 5.1M shares are issuable from outstanding warrants and 9.4M pre-funded warrants issued for potential future stock.
$MRLN (MC: $249M)
- Private Placement: 8M shares of common stock at $10.00/share, totaling ~$80M including warrants.
- New Warrants: 4M underlying shares issued alongside the private placement.
- Anti-dilution: Existing 12% Series A Convertible Preferred Stock and other warrants to have conversion/exercise prices adjusted downwards.
$GHRS (MC: $1.2B)
- Registered Direct: 6.53M ordinary shares offered at $18.00, raising $117.5M.
- 2.59M ordinary shares issuable from outstanding options @ ~$3.87, as of Dec 31, 2025.
- 1.12M additional ordinary shares reserved for future issuance under equity incentive plan.
$OPFI (MC: $778M)
- Merger consideration for $130.7M BNCCORP acquisition to issue 1.90 Class A shares per BNCC share upon Q4 2026 close.
- Corporate simplification involved exchanging OpCo Units (1:1) for Class A common stock; 734,851 shares issued on April 28, 2026, and remaining OpCo Units cancelled.
$TWO (MC: $1.2B)
- This filing (Form 8-K dated April 28, 2026) primarily discusses an amendment to an Agreement and Plan of Merger. It focuses on changes to the merger consideration (cash per share) and termination fees related to the acquisition by CrossCountry Intermediate Holdco, LLC (CCM).
- There are NO explicit stock dilution events or instruments (warrants, convertible notes, convertible preferred stock, ATM programs, equity lines, direct offerings, PIPE deals, or stock compensation plans with specific share reservations) detailed within this specific Form 8-K filing.
- The document mentions that the Common Stock is registered and traded, and lists existing preferred stock and senior notes, but it does not describe any new issuance or potential issuance of equity that would result in dilution. The "FORWARD-LOOKING STATEMENTS" section discusses general risks and uncertainties that *could* affect future results, including changes in the availability and terms of financing, but it does not present a concrete dilution event.
$DMII (MC: $526M)
- Stock Compensation: 175K ordinary shares for CFO Saleem Elmasri, 250K for CEO Roger E. Bendelac.
- Shares to be issued upon closing of initial business combination.
$DVLT (MC: $202M)
- Proposed $120M upfront payment from Scilex for a revenue participation arrangement.
- Transaction is a proposed term sheet; explicit share issuance not specified, but may lead to future equity considerations.
$FLXS (MC: $300M)
- The filing describes a stock repurchase agreement. A stock repurchase reduces the number of outstanding shares, which is the opposite of dilution. Dilution occurs when the number of outstanding shares increases, leading to a decrease in the ownership percentage of existing shareholders.
$CDNA (MC: $1.1B)
- Item 8.01 Other Events.
- Type of instrument: Common stock repurchase program
- Dollar amounts: $100,000,000
$DMAA (MC: $356M)
- 425,000 ordinary shares to be issued as compensation upon business combination close.
- 175,000 shares for Titan Advisory Services LLC and 250,000 shares for Aleutian Equity Holdings LLC.
- The 175,000 shares for Titan represent a change from a previously agreed 100,000 shares due to non-issuance.